Skip to main content
RNAZ logo

TransCode Therapeutics, Inc.

RNAZNASDAQHealthcareBiotechnology

$1.70Today:- (-)1Y −88.18%

As of Oct 16, 2026 close

Market cap
$1.72M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$1.52$15.49
Volume (live)
-
Avg. volume (3M)
46.60K

TransCode Therapeutics (RNAZ) Financial Ratios

For fiscal 2025 (fiscal year ended Dec 31, 2025), TransCode Therapeutics had return on equity of -46.3%, a current ratio of 6.29 (up from 2.56) and return on assets of -14.1% (up from -157.1%). A current ratio of 6.29 means current assets exceed current liabilities.

TransCode Therapeutics Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/B Ratio0.04-1.162.522.611.56-
Price/Tangible Book--2.522.611.56-
Enterprise Value Ratios
Profitability & Returns
Return on Equity (ROE)-46.26%--759.85%-148.57%-80.53%103.76%
Return on Assets (ROA)-14.14%-157.06%-190.26%-76.30%-32.04%-115.35%
Return on Invested Capital (ROIC)-----859.47%
Return on Capital Employed (ROCE)-12.10%-346.30%-1156.50%-575.00%-30.10%-183.48%
Leverage & Solvency Ratios
Debt/Equity--0.020.28---0.61
Debt/EBITDA------2.87
Debt/FCF------4.23
Liquidity Ratios
Current Ratio6.292.561.281.708.972.05
Quick Ratio5.372.100.791.158.222.05
Efficiency Ratios
Yield & Distribution Ratios
Earnings Yield-553.44%-714.08%-448.43%-207.69%-21.44%-
FCF Yield-311.72%-569.30%-437.89%-187.57%-17.30%-
Buyback Yield-5392.22%----0.00%
Total Return-----0.00%

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About TransCode Therapeutics Financial Ratios

What is TransCode Therapeutics's return on equity?

TransCode Therapeutics's return on equity (ROE) was -46.3% for fiscal 2025 (period ended Dec 31, 2025).

What is return on equity (ROE)?

Return on equity is net income divided by shareholders' equity. It measures how much profit a company generates from the capital its shareholders have invested. Full definition